Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1999 2
2000 1
2001 3
2002 4
2003 1
2004 6
2005 8
2006 12
2007 7
2008 10
2009 9
2010 7
2011 1
2012 9
2013 10
2014 12
2015 9
2016 7
2017 10
2018 6
2019 7
2020 13
2021 8
2022 11
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Locus coeruleus: a new look at the blue spot.
Poe GR, Foote S, Eschenko O, Johansen JP, Bouret S, Aston-Jones G, Harley CW, Manahan-Vaughan D, Weinshenker D, Valentino R, Berridge C, Chandler DJ, Waterhouse B, Sara SJ. Poe GR, et al. Among authors: weinshenker d. Nat Rev Neurosci. 2020 Nov;21(11):644-659. doi: 10.1038/s41583-020-0360-9. Epub 2020 Sep 17. Nat Rev Neurosci. 2020. PMID: 32943779 Free PMC article. Review.
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone.
Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, Rea W, Ventriglia EN, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter GC, Weinshenker D, Zarate CA Jr, Casadó V, Baumann MH, Pardo L, Ferré S, Michaelides M. Levinstein MR, et al. Among authors: weinshenker d. Mol Psychiatry. 2023 Dec 25. doi: 10.1038/s41380-023-02353-z. Online ahead of print. Mol Psychiatry. 2023. PMID: 38145984
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D. Levey AI, et al. Among authors: weinshenker d. Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452. Brain. 2022. PMID: 34919634 Free PMC article. Clinical Trial.
Neuroscience: fragile dopamine.
Weinshenker D, Warren ST. Weinshenker D, et al. Nature. 2008 Oct 2;455(7213):607-8. doi: 10.1038/455607a. Nature. 2008. PMID: 18833269 No abstract available.
Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone.
Michaelides M, Levinstein M, De Oliveira P, Casajuana-Martin N, Quiroz C, Budinich R, Rais R, Rea W, Ventriglia E, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter G, Weinshenker D, Zarate C, Casado V, Baumann M, Pardo L, Ferre S. Michaelides M, et al. Among authors: weinshenker d. Res Sq [Preprint]. 2023 Mar 23:rs.3.rs-2644719. doi: 10.21203/rs.3.rs-2644719/v1. Res Sq. 2023. PMID: 36993715 Free PMC article. Updated. Preprint.
165 results